What it's for (Indications)
- Nifuroxazide is indicated for the treatment of acute infectious diarrhea of presumed bacterial origin, particularly when there are no signs of invasive infection such as fever, systemic toxicity, or the presence of blood or significant mucus in the stools.
- It is used as an adjuvant to rehydration therapy, which remains the cornerstone of management for acute diarrheal illnesses.
- Its efficacy is primarily localized within the gastrointestinal lumen due to minimal systemic absorption, targeting pathogenic bacteria responsible for common forms of gastroenteritis.
- The use of nifuroxazide should be considered in conjunction with clinical assessment and, where appropriate, microbiological testing to confirm bacterial etiology and exclude non-bacterial causes or severe invasive infections requiring systemic antibiotics.
- This localized action helps reduce bacterial load and alleviate symptoms without contributing to widespread antibiotic resistance or systemic side effects.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of nifuroxazide varies by age and formulation. For adults, the typical recommended dose is 200 mg administered orally, three to four times daily, for a treatment duration generally ranging from 3 to 7 days. For pediatric patients, the dosage must be carefully adjusted based on age and body weight, often available in suspension form for easier administration. For instance, children over 6 years may receive 200 mg three times daily, while younger children (e.g., 2-6 years) might be prescribed 100 mg three times daily. Infants under 1 month of age should not be administered nifuroxazide under any circumstances. It is crucial to adhere strictly to the prescribed dosage and duration of treatment, and to not exceed the recommended course even if symptoms resolve earlier, to ensure complete eradication of susceptible bacteria and prevent recurrence or development of resistance. Administration with or without food does not significantly alter its efficacy. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated due to its localized action within the gastrointestinal tract, nifuroxazide can cause certain side effects.
- The most commonly reported adverse reactions are gastrointestinal in nature and include nausea, vomiting, and abdominal pain or discomfort.
- These symptoms are usually mild and transient and often resolve without intervention.
- Less frequently, hypersensitivity reactions may occur, manifesting as skin rashes, urticaria (hives), pruritus (itching), or angioedema (swelling of the face, lips, tongue, or throat).
- In rare instances, more severe allergic reactions or anaphylaxis have been reported, necessitating immediate medical attention.
- Patients should be advised to discontinue the medication and seek medical advice if they experience any signs of a severe allergic reaction.
- Due to its minimal systemic absorption, systemic side effects typically associated with systemically active antibiotics, such as liver or kidney dysfunction, are exceptionally rare with nifuroxazide.
Serious Warnings
- Black Box Warning: **Serious Warnings** While nifuroxazide does not carry a formal FDA Black Box Warning as it is not approved for use in the United States, several serious considerations warrant careful attention. Nifuroxazide is strictly contraindicated in infants younger than one month of age due to potential safety concerns and an increased risk of adverse effects in this vulnerable population. There is a risk of severe hypersensitivity reactions, including anaphylaxis and angioedema, which can be life-threatening. Patients experiencing any signs of severe allergic reaction, such as swelling of the face, lips, tongue, or throat, difficulty breathing, or severe rash, must discontinue the medication immediately and seek urgent medical attention. Furthermore, nifuroxazide should not be used for invasive diarrhea, which is characterized by high fever, blood in the stools, or signs of systemic infection, as it is not effective against systemically spread pathogens and may delay appropriate systemic antibiotic treatment. Prolonged use beyond the recommended duration is discouraged to prevent the selection of resistant bacterial strains and potential superinfections. Healthcare providers must emphasize the critical importance of concurrent rehydration therapy, as nifuroxazide is an adjunct treatment and not a substitute for fluid and electrolyte replacement in managing acute diarrhea.
- Nifuroxazide should be used with caution and is not a substitute for comprehensive rehydration therapy, which is paramount in managing acute diarrhea, especially in children and the elderly.
- It is not indicated for invasive diarrhea, characterized by signs like high fever, systemic toxicity, or the presence of blood or significant mucus in stools, as such conditions usually require systemic antibiotics.
- Prolonged use of nifuroxazide beyond the recommended duration should be avoided as it may lead to the selection of resistant bacterial strains or the development of superinfections.
- Patients should be advised to avoid alcohol consumption during treatment with nifuroxazide, as a disulfiram-like reaction (characterized by flushing, headache, nausea, vomiting, chest pain) is theoretically possible, although rare due to its minimal systemic absorption.
- Hypersensitivity reactions, including severe allergic responses, can occur, and the drug should be discontinued immediately if such reactions develop.
- Caution is also advised in patients with pre-existing gastrointestinal conditions, and use in pregnant or breastfeeding women should only be considered if clearly necessary, with potential risks and benefits thoroughly assessed by a healthcare provider, weighing the localized action against any potential systemic exposure.
How it Works (Mechanism of Action)
Nifuroxazide is an oral nitrofuran derivative that acts primarily as a local intestinal antiseptic. Its mechanism of action involves interfering with key bacterial enzymatic processes and inhibiting bacterial protein synthesis. Specifically, nifuroxazide is thought to disrupt the bacterial respiratory chain, inhibit several bacterial dehydrogenase enzymes, and interfere with DNA replication and transcription. These multifaceted actions lead to both bacteriostatic (inhibiting growth) and bactericidal (killing bacteria) effects against a broad spectrum of common enteropathogenic bacteria, including *Escherichia coli*, *Salmonella* species, *Shigella* species, *Staphylococcus aureus*, and *Clostridium perfringens*, which are frequently implicated in acute infectious diarrhea. A significant advantage of nifuroxazide is its minimal systemic absorption from the gastrointestinal tract, allowing it to exert its antimicrobial effects predominantly within the intestinal lumen, thereby reducing the risk of systemic side effects, minimizing impact on the beneficial gut microbiota outside the target pathogens, and limiting the contribution to widespread antibiotic resistance.
Commercial Brands (Alternatives)
No other brands found for this formula.